# GCC Microbiome Sequencing Services Market > GCC Microbiome Sequencing Services Market Research Report: By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Others) andBy Application (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 17.7% - **2024:** $ 41.67 Million - **2025:** $ 49.05 Million - **2035:** $ 250.22 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) **Report ID:** MRFR/HC/52149-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-microbiome-sequencing-services-market-53911 --- ## Market Summary ## **GCC Microbiome Sequencing Services Market Overview****:** As per MRFR analysis, the GCC Microbiome Sequencing Services Market Size was estimated at 59.62 (USD Million) in 2023. The GCC Microbiome Sequencing Services Market Industry is expected to grow from 65.52(USD Million) in 2024 to 335 (USD Million) by 2035. The GCC Microbiome Sequencing Services Market CAGR (growth rate) is expected to be around 15.991% during the forecast period (2025 - 2035). ### **Key GCC Microbiome Sequencing Services Market Trends Highlighted** The GCC Microbiome Sequencing Services Market is experiencing substantial growth as a result of the growing recognition of the microbiome's influence on human health and disease. The GCC region's governments are making significant investments in biotechnology and healthcare infrastructure, which has resulted in significant progress in the fields of genomics and microbiome research. Countries such as the United Arab Emirates and Saudi Arabia have implemented initiatives to encourage scientific innovation, which has resulted in an increase in the investigation of the microbiome.  This trend of government support encourages collaboration between academic institutions and research facilities, thereby increasing the demand for microbiome sequencing services. In recent years, there has been a growing interest in personalized medicine, with microbiome analysis being considered a critical component of the development of individualized healthcare solutions. The demand for sequencing services is increasing as healthcare providers seek to customize treatments based on microbiome profiles. Furthermore, the research community is increasingly interested in investigating the potential applications of microbiome sequencing in the fields of environmental science and agriculture.  This multidisciplinary approach creates additional opportunities for service providers by expanding the GCC market beyond clinical applications. Additionally, the microbiome-related research and services sector has significant potential for expansion due to the growing investments of the private sector and businesses that concentrate on health technology innovations.In the GCC market, microbiome sequencing is becoming more accessible and affordable due to advancements in data analysis tools and sequencing technologies. The microbiome sequencing sector is on the brink of significant growth as the region continues to embrace biotechnology and genomics, creating a plethora of opportunities for companies operating in this sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **GCC Microbiome Sequencing Services Market Drivers** ### **Increasing Focus on Personalized Medicine** The GCC Microbiome Sequencing Services Market Industry is witnessing a growing emphasis on personalized medicine, which aims to tailor treatments based on individual patient profiles. According to the Gulf Health Council, personalized medicine has the potential to enhance treatment efficacy by 30% compared to traditional methods. Organizations like the Saudi Arabian Ministry of Health are investing in genomic research initiatives to provide tailored healthcare solutions.Such investments have resulted in increased funding for Research and Development (R&D) in microbiome studies, which can lay the groundwork for personalized therapies. This trend is pushing healthcare providers in the GCC to partner with sequencing service providers, thereby driving market growth. ### **Rising Incidence of Chronic Diseases** Chronic diseases such as diabetes, obesity, and cardiovascular issues are on the rise in the GCC region, significantly impacting healthcare systems. The World Health Organization has reported a 20% surge in chronic disease cases in GCC countries over the past decade. This alarming trend has prompted government bodies, such as the UAE Ministry of Health and Prevention, to initiate public health campaigns that emphasize the importance of microbiome research in disease prevention and management.As these organizations advocate for advanced diagnostic methods, the demand for microbiome sequencing services is poised to escalate. ### **Collaborative Research Initiatives** The GCC Microbiome Sequencing Services Market Industry is benefiting from collaborative research initiatives involving academic institutions and healthcare organizations. For instance, prominent universities in the region, such as King Abdullah University of Science and Technology, are launching projects aimed at studying the gut microbiome's impact on various diseases. As these institutions collaborate with biotech firms like Novartis and Roche, they are driving innovation in microbiome-related therapies and diagnostics.These partnerships are expected to enhance funding for microbiome sequencing projects, thus accelerating market growth in the GCC. ## **GCC Microbiome Sequencing Services Market Segment Insights****:** ### **Microbiome Sequencing Services Market Technology Insights** The Technology segment of the GCC Microbiome Sequencing Services Market is integral to the rapid advancement of genomic research and microbiome understanding in the region. This segment encompasses various methodologies, each offering unique capabilities and strengths that cater to a diverse range of applications. For instance, Sequencing by Litigation (SBL) is crucial for its ability to accurately capture the complexity of microbial communities, delivering insights that can greatly enhance disease prevention and treatment strategies. Similarly, Sequencing by Synthesis (SBS) is widely recognized for its high-throughput capabilities, enabling researchers to process large samples quickly and efficiently, which is particularly beneficial in both clinical and environmental studies.  Moreover, Shotgun Sequencing has become a dominant technique due to its comprehensive approach to capturing a vast array of genetic material, making it invaluable in both metagenomic studies and the exploration of microbial diversity. Targeted Gene Sequencing enhances precision by focusing on specific genes or regions of interest, thereby providing detailed information on gene functions and interactions, which is critical for personalized medicine initiatives. RNA Sequencing, on the other hand, is pivotal for understanding gene expression and regulation, further contributing to advancements in biotechnology and therapeutic development.  Collectively, these technologies not only support the GCC Microbiome Sequencing Services Market's growth but also highlight opportunities for innovation in microbiome research and applications across healthcare, agriculture, and environmental sustainability.As the GCC region continues to invest in biotechnology and genomic research, the demand for these sequencing technologies is expected to rise significantly. The growing awareness of the impact of the microbiome on health, disease, and ecosystems further propels this market segment, opening pathways for collaboration among research institutions, governmental bodies, and private enterprises.  This evolving landscape presents opportunities for ongoing development in sequencing technology, driven by advancements in computational biology and data analytics, which complement these traditional methods and enhance their capabilities. Understanding the trajectory of these technologies and their significance in the GCC's microbiome sequencing services landscape underlines the transformative potential they hold for addressing health-related challenges and fostering economic growth in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Microbiome Sequencing Services Market Application Insights** The Application segment of the GCC Microbiome Sequencing Services Market plays a critical role in advancing healthcare by harnessing the power of microbial genomics. A major focus is on gastrointestinal diseases, where microbiome analysis helps in understanding complex disorders, contributing to tailored therapeutics and better patient outcomes. Infectious diseases are another key area, as microbiome sequencing facilitates the identification of pathogens and resistance mechanisms, which enhances treatment strategies. Central nervous system (CNS) diseases are increasingly recognized for their link to gut microbiota, driving research into innovative interventions that may alleviate conditions such as Alzheimer’s and Parkinson’s.Oncology represents a significant frontier, with microbiome insights potentially influencing tumor growth and responses to immunotherapy.  Other applications also contribute to an expanding knowledge base, addressing diverse health issues through microbiome analysis. The increased recognition of the microbiome’s impact on health is driving market growth in the GCC region, as healthcare stakeholders invest in advanced sequencing technologies and platforms. This focus on integrated approaches underscores the importance of understanding microbial dynamics in improving public health outcomes across various medical disciplines. ## **GCC Microbiome Sequencing Services Market Key Players and Competitive Insights****:** The GCC Microbiome Sequencing Services Market is witnessing significant growth, driven by increasing awareness of the role microbiomes play in health, agriculture, and environmental sustainability. The competitive landscape in this market is shaped by the rapid advancement of sequencing technologies, enabling a diverse array of players to offer sophisticated microbiome analysis solutions. As interest in personalized medicine and the application of microbiome research spans various sectors, including healthcare, pharmaceuticals, and food production, companies are actively diversifying their services to meet the unique demands of this burgeoning market.  The competitive insights reveal that firms are not only enhancing their technological capabilities but also focusing on strategic collaborations, acquisitions, and geographical expansions within the Gulf Cooperation Council region to solidify their market presence.CosmosID is well-established in the GCC Microbiome Sequencing Services Market, primarily recognized for its advanced bioinformatics platform that provides precise microbial identification and characterization.  The company boasts a robust infrastructure for high-throughput sequencing, which allows for comprehensive analysis of complex microbiomes across various applications such as healthcare diagnostics, environmental monitoring, and agronomy. CosmosID's strengths lie in its proprietary analytics that enable clients to make data-driven decisions, thereby enhancing the accuracy and efficiency of microbiome research. Furthermore, CosmosID has fostered collaborative partnerships with research institutions and healthcare providers across the GCC region, facilitating the expansion of its service offerings and broadening its influence in the market.Zymo Research presents itself as a prominent player in the GCC Microbiome Sequencing Services Market, known for its innovative products and solutions that support microbiome research.  The company's key offerings include specialized kits for DNA and RNA extraction, library preparation, and comprehensive sequencing services tailored to microbiome studies. Zymo Research has established a strong market presence in the GCC region due to its commitment to quality and its ability to provide educational resources and technical support to its customers. The company has been actively involved in mergers and acquisitions, strengthening its expertise and expanding its portfolio of services specifically designed for microbiome applications. Zymo Research's strengths encompass its extensive product range, customer-centric approach, and an established network of collaborations that reinforce its position in the microbiome sequencing landscape within the GCC market. ### **Key Companies in the GCC Microbiome Sequencing Services Market Include** - CosmosID - Zymo Research - Asuragen - Pacific Biosciences - Qiagen - Stratos Genomics - Genomic Health - Thermo Fisher Scientific - Illumina - Ginkgo Bioworks - Oxford Nanopore Technologies - Genomatix - Microbiome Insights - Genomatica - Becton Dickinson ## **GCC Microbiome Sequencing Services Market Industry Developments** The GCC Microbiome Sequencing Services Market has experienced significant developments recently, including strong investments and technological advancements. In 2023, several companies like Qiagen and Illumina have expanded their operations in the GCC region, responding to the increasing demand for microbiome analysis in healthcare and agriculture.  Alongside this growth, the region has witnessed collaborations for Research and Development, fostering an innovative environment, particularly in Qatar and the UAE. In terms of mergers and acquisitions, there have been no major publicly known transactions among the specified companies in the last few months; however, the trend towards consolidation remains a focal point for future activity. For instance, Ginkgo Bioworks has been in discussions regarding potential partnerships with local firms to enhance its service offerings.  The GCC governments are also prioritizing biotechnology within their economic diversification strategies, aiming to turn the region into a hub for life sciences, thereby further boosting market potential. As a result, the valuation of the microbiome sequencing market is projected to grow significantly, driven by increasing awareness of personalized medicine and the ongoing digitization of healthcare services across the GCC countries. ## **GCC Microbiome Sequencing Services Market Segmentation Insights** ### **Microbiome Sequencing Services Market Technology****Outlook** - Sequencing by Litigation (SBL) - Sequencing by Synthesis (SBS) - Short Gun Sequencing - Targeted Gene Sequencing - RNA Sequencing - Others ### **Microbiome Sequencing Services Market Application****Outlook** - Gastrointestinal Diseases - Infectious Diseases - CNS Diseases - Oncology - Others ## Market Drivers ### Investment in Biotechnology Investment in biotechnology within the GCC is a significant driver for the microbiome sequencing-services market. Governments and private sectors are increasingly allocating funds to support research and development in biotechnology, which includes microbiome studies. For instance, the GCC countries have invested over $1 billion in biotechnology initiatives in recent years, fostering innovation and technological advancements. This influx of capital is likely to enhance the capabilities of microbiome sequencing services, making them more accessible and efficient. As a result, the market is expected to expand, with more companies entering the field and offering diverse sequencing services tailored to various health needs. ### Growing Awareness of Gut Health The increasing awareness of gut health among consumers in the GCC region is driving the microbiome sequencing-services market. As individuals become more informed about the role of gut microbiota in overall health, there is a rising demand for services that analyze and optimize gut flora. This trend is reflected in the growing number of health and wellness products that emphasize gut health, which has seen a market growth of approximately 15% annually. The microbiome sequencing-services market is positioned to benefit from this shift, as consumers seek personalized insights into their microbiomes to improve health outcomes. Furthermore, educational campaigns by health organizations are likely to enhance public understanding, thereby expanding the customer base for microbiome sequencing services. ### Rising Prevalence of Chronic Diseases The rising prevalence of chronic diseases in the GCC region is a critical driver for the microbiome sequencing-services market. Conditions such as obesity, diabetes, and gastrointestinal disorders are becoming increasingly common, prompting a search for innovative solutions. Research indicates that the microbiome plays a crucial role in the development and management of these diseases, leading healthcare providers to explore microbiome sequencing as a diagnostic tool. The market for microbiome sequencing services is projected to grow by approximately 20% over the next five years, driven by the need for personalized treatment plans that consider individual microbiome profiles. This trend highlights the potential of microbiome analysis in improving health outcomes for patients with chronic conditions. ### Technological Integration in Healthcare The integration of advanced technologies in healthcare is significantly influencing the microbiome sequencing-services market. Innovations such as artificial intelligence and machine learning are being utilized to analyze complex microbiome data, providing deeper insights into health and disease. This technological evolution is expected to enhance the accuracy and efficiency of microbiome sequencing services, making them more appealing to healthcare providers and patients alike. As the GCC region embraces digital health solutions, the microbiome sequencing-services market is likely to experience substantial growth, with an anticipated increase in service adoption rates. The convergence of technology and healthcare is paving the way for more personalized and effective health interventions. ### Collaborations and Partnerships in Research Collaborations and partnerships between academic institutions, healthcare providers, and private companies are emerging as a vital driver for the microbiome sequencing-services market. These alliances facilitate knowledge sharing and resource pooling, leading to advancements in microbiome research and its applications. In the GCC, several universities are partnering with biotech firms to explore the therapeutic potential of microbiome analysis, which is expected to accelerate the development of new sequencing services. Such collaborations not only enhance the scientific understanding of microbiomes but also promote the commercialization of innovative services. The microbiome sequencing-services market stands to benefit from these partnerships, as they are likely to result in a broader range of offerings and improved service quality. ## Future Outlook The [Microbiome Sequencing Services Market](https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532) is projected to grow at a 17.7% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing health awareness, and technological innovations. **New opportunities:** - Development of mobile microbiome analysis units for remote diagnostics. - Partnerships with healthcare providers for integrated microbiome health solutions. - Launch of subscription-based microbiome monitoring services for consumers. By 2035, the market is expected to achieve substantial growth, driven by innovative service offerings and strategic partnerships. ## Segment Insights ### By Technology: Sequencing by Synthesis (Largest) vs. RNA Sequencing (Fastest-Growing) In the GCC microbiome sequencing-services market, Sequencing by Synthesis (SBS) leads in market share, driven by its high accuracy and cost-effectiveness. This segment accounts for the majority of revenues, attributed to widespread adoption in clinical applications and research. Other techniques such as Sequencing by Litigation (SBL) and Short Gun Sequencing hold smaller shares but serve specific applications that cater to niche markets, making the overall landscape competitive. Growth trends indicate a rapid expansion in RNA Sequencing services, fueled by increasing demand for gene expression studies and advancements in technology. The growing focus on personalized medicine and healthcare has further accelerated the uptake of these services. Innovations in data analysis and the development of more efficient sequencing platforms are key factors contributing to this growth. Technology: Sequencing by Synthesis (Dominant) vs. RNA Sequencing (Emerging) Sequencing by Synthesis (SBS) stands out as the dominant technology within the GCC microbiome sequencing-services market, due to its established methodology and proven track record in generating high-quality data. It is favored by researchers and clinicians alike for applications requiring reliable sequencing data. Conversely, RNA Sequencing is rapidly emerging, gaining traction for its ability to provide insights into gene expression dynamics. This technology is particularly crucial for studies related to diseases and is benefits from technological advancements that enhance its efficiency and accuracy. Both segments are essential for the future of research in the microbiome field, with SBS leading in current applications while RNA Sequencing positions itself as a key player for upcoming innovations. ### By Application: Gastrointestinal Diseases (Largest) vs. Oncology (Fastest-Growing) The GCC microbiome sequencing-services market exhibits a diverse application landscape, with Gastrointestinal Diseases commanding the largest market share. This segment benefits from the rising incidence of gastrointestinal disorders and the growing awareness among healthcare providers regarding microbiome's role in overall health. In contrast, the Oncology segment, although currently smaller, is rapidly evolving due to increased research and development efforts directed towards personalized medicine and targeted therapies using microbiome insights. Growth trends in the GCC microbiome sequencing-services market indicate a shift towards more specialized services, especially in Oncology, which is recognized as the fastest-growing segment. Escalating investment in clinical trials and innovative therapies is driving demand in this field. Furthermore, awareness regarding the microbiome's influence on treatment outcomes is propelling interest in gastrointestinal health, which remains a significant focus area for expansion within the market. Gastrointestinal Diseases (Dominant) vs. Oncology (Emerging) Gastrointestinal Diseases are characterized by a significant focus on the gut microbiome's role in health and disease management. This segment is established, leveraging extensive research and clinical applications to address a range of conditions from IBS to IBD. In contrast, the Oncology segment is emerging as a vital area, integrating microbiome data with therapeutic strategies for cancer treatment. This innovative approach seeks to harness the microbiome's potential in enhancing treatment efficacy and minimizing side effects. Both segments are pivotal for the GCC microbiome sequencing-services market, yet they cater to distinct medical needs and have varied growth trajectories. ## Competitive Benchmarking The microbiome sequencing-services market is currently characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and advancements in genomic technologies. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Qiagen (DE) are at the forefront, leveraging their technological expertise and extensive product portfolios to capture market share. Illumina (US) focuses on innovation in sequencing technologies, while Thermo Fisher Scientific (US) emphasizes comprehensive solutions that integrate sequencing with bioinformatics. Qiagen (DE) is strategically positioned through its strong emphasis on sample preparation and analysis, which complements its sequencing capabilities. Collectively, these strategies foster a competitive environment that is increasingly reliant on technological advancements and integrated service offerings.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with a mix of established players and emerging companies vying for market presence. This fragmentation allows for diverse offerings, yet the influence of key players remains substantial, as they set industry standards and drive innovation. In October Illumina (US) announced a partnership with a leading healthcare provider to develop a new platform for microbiome analysis, aiming to enhance diagnostic capabilities. This strategic move is likely to bolster Illumina's position in the market by expanding its service offerings and integrating its technology into clinical settings, thereby addressing the growing demand for personalized healthcare solutions. In September Thermo Fisher Scientific (US) launched a new line of microbiome sequencing kits designed for high-throughput applications. This introduction not only reflects the company's commitment to innovation but also positions it to capture a larger share of the research market, where demand for efficient and scalable solutions is on the rise. The launch is expected to enhance customer engagement and drive revenue growth in the competitive landscape. In August Qiagen (DE) expanded its product portfolio by acquiring a microbiome-focused startup, which specializes in advanced bioinformatics tools. This acquisition is indicative of Qiagen's strategy to enhance its analytical capabilities and provide comprehensive solutions that integrate sequencing with data analysis. Such strategic moves are likely to strengthen its competitive edge and appeal to a broader customer base. As of November current trends in the microbiome sequencing-services market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in data analysis. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than price-based competition. Companies that can reliably deliver advanced solutions while optimizing their supply chains are likely to emerge as leaders in this rapidly evolving market. ## Recent News & Developments The GCC Microbiome Sequencing Services Market has experienced significant developments recently, including strong investments and technological advancements. In 2023, several companies like Qiagen and Illumina have expanded their operations in the GCC region, responding to the increasing demand for microbiome analysis in healthcare and agriculture.  Alongside this growth, the region has witnessed collaborations for Research and Development, fostering an innovative environment, particularly in Qatar and the UAE. In terms of mergers and acquisitions, there have been no major publicly known transactions among the specified companies in the last few months; however, the trend towards consolidation remains a focal point for future activity. For instance, Ginkgo Bioworks has been in discussions regarding potential partnerships with local firms to enhance its service offerings.  The GCC governments are also prioritizing biotechnology within their economic diversification strategies, aiming to turn the region into a hub for life sciences, thereby further boosting market potential. As a result, the valuation of the microbiome sequencing market is projected to grow significantly, driven by increasing awareness of personalized medicine and the ongoing digitization of healthcare services across the GCC countries. ## Report Scope | MARKET SIZE 2024 | 41.67(USD Million) | | --- | --- | | MARKET SIZE 2025 | 49.05(USD Million) | | MARKET SIZE 2035 | 250.22(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.7% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) | | Segments Covered | Technology, Application | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in microbiome sequencing-services market. | | Key Market Dynamics | Rising demand for personalized medicine drives growth in microbiome sequencing services across the GCC region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What is the projected market valuation for the GCC microbiome sequencing-services market by 2035?** A: The projected market valuation for the GCC microbiome sequencing-services market by 2035 is $250.22 Million. **Q: What was the overall market valuation in 2024?** A: The overall market valuation in 2024 was $41.67 Million. **Q: What is the expected CAGR for the GCC microbiome sequencing-services market during the forecast period 2025 - 2035?** A: The expected CAGR for the GCC microbiome sequencing-services market during the forecast period 2025 - 2035 is 17.7%. **Q: Which technology segment had the highest valuation in 2024?** A: In 2024, the Sequencing by Synthesis (SBS) segment had the highest valuation at $60.0 Million. **Q: What are the key applications driving the GCC microbiome sequencing-services market?** A: Key applications driving the market include Oncology, Gastrointestinal Diseases, and Infectious Diseases, with valuations reaching $70.0 Million, $60.0 Million, and $50.0 Million respectively. **Q: Who are the leading companies in the GCC microbiome sequencing-services market?** A: Leading companies in the market include Illumina, Thermo Fisher Scientific, Zymo Research, Qiagen, and Microbiome Insights. **Q: What is the valuation range for the Short Gun Sequencing technology segment?** A: The valuation range for the Short Gun Sequencing technology segment is between $8.0 Million and $50.0 Million. **Q: How does the valuation of the Targeted Gene Sequencing segment compare to others?** A: The Targeted Gene Sequencing segment, with a valuation range of $7.0 Million to $40.0 Million, indicates a competitive position among other technology segments. **Q: What is the valuation range for the application of CNS Diseases in 2024?** A: The valuation range for the application of CNS Diseases in 2024 was between $7.0 Million and $40.0 Million. **Q: What does the future hold for the Others segment in technology and application?** A: The Others segment in technology and application shows potential with valuations ranging from $5.67 Million to $25.22 Million and $6.67 Million to $30.22 Million respectively. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-microbiome-sequencing-services-market-53911*